An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.

A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

BACKGROUND Medical therapies for hidradenitis suppurativa (HS) are often ineffective. Tumor necrosis factor-alpha inhibitors may be a potential treatment for patients with moderate to severe HS. OBJECTIVES We sought to evaluate the safety and efficacy of etanercept for patients with severe HS. METHODS We conducted a phase II clinical trial of etanercept (50 mg/wk subcutaneously) in patients...

Microbial profile and antibiotic susceptibility of bacteria isolated from patients with hidradenitis suppurativa

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of unknown etiology. There is evidence that bacteria may contribute to initiating the inflammatory response in HS patients. To date, data on bacteria found in HS lesions and their resistance rates are rare. Methods: The results of bacterial cultures and antibiotic susceptibility of the isolated bacteria obtained fr...

Treatment of hidradenitis suppurativa with etanercept injection.

OBJECTIVES To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations. DESIGN Single-center, randomized, prospective, double-blind, placebo-controlled study. SETTING Academic dermatology practice. PATIENTS Twenty patients with active moderate to s...

Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study

Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.

Hidradenitis suppurativa (HS) is a common inflammatory skin disease. Medical treatment is often disappointing and in severe disease surgery remains the therapy of choice. Extensive surgery may be effective but also mutilating. Patients experience a significant reduction in quality of life and the need for new treatment modalities are urgent. In recent years patients with HS have been treated of...